Group items tagged

Cerebral palsy (CP) is a general term for a group of permanent movement problems that do not get worse over time. They cause physical disability,mainly in the areas of body movement.There may also be problems with sensation, depth perception,so you use Cerebral palsy wheelchair and communication ability. Difficulty with cognition and epilepsy are found in about one-third of cases. There are subtypes including a type characterized by spasticity, a type characterized by poor coordination, and types which feature both symptoms or neither. Cerebral palsy is caused by damage to the motor control centers of the developing brain and can occur during pregnancy, during childbirth, or after birth up to about age three.About 2% of all cerebral palsy cases are believed to be due to a genetic cause.Cerebral palsy is not an infectious disease and is not contagious. Most cases are diagnosed at a young age rather than during adolescence or adulthood.CP 2 Pediatric Wheelchair is very useful for cerebral palsy person. Improvements in the care of newborns has helped reduce the number of babies who develop cerebral palsy and increased the survival of those with very low birth weights.There is no cure, with efforts attempting to treat and prevent complications. It occurs in about 2.1 per 1,000 live births.Physical therapy may help. Cerebral refers to the cerebrum, which is the affected area of the brain. The disorder may often involve connections between the cortex and other parts of the brain such as the cerebellum. The root word "palsy" means "paralysis". In medicine, this is often used in reference to the paralysis or weakness that often accompanies nerve damage, loss of sensation or muscle disorders involving uncontrollable movements such as trembling or shaking.

MD Innovative provides reasonable and quality services to various clients. We considered being a technological hub that provides the ultimate solution to the technical problems faced by our customers. We design customers own design that they have thought to make it possible on the webpage to show to others they wanted to. Our Services Website design and development, E-commerce sites, Mobile application development, Search Engine Optimization, Social Media Marketing, and Amazon account management.

Prince Charles formally opened a new 1 billion pound AstraZeneca research and development (R&D) facility in Cambridge on Tuesday (November 23), as the company aims to fuel the growth of its drug pipeline. AstraZeneca has supplied two billion doses of its Covid-19 vaccine, developed at Oxford University, and is also looking to bring a preventative antibody cocktail against Covid-19 to market. Prince Charles, son of Queen Elizabeth and heir to the throne, saw an exhibit on the pandemic and a demonstration of how augmented reality headsets can help with lab work, before hearing about the company's net-zero targets. "The last two years have been some of the most difficult of a generation," Prince Charles said in a speech.

The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future. It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they need them the most. The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot. Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used. By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics, decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.

Digestive issues such as constipation, dysphagia and irritable bowel syndrome (IBS) may be precursors of Parkinson's disease, according to research published in the journal Gut. Gastrointestinal symptoms are thought to precede the development of some cerebrovascular disease, including brain aneurysm or Alzheimer's disease, and it has been suggested (Braak's hypothesis) that gut conditions may precede the development of Parkinson's disease too. To test this hypothesis, researchers used data from a US nationwide medical record network (TriNetX) to compare 24,624 people who had been diagnosed with Parkinson's disease of unknown cause with those who had been diagnosed with other neurological conditions - Alzheimer's disease (19,046) or cerebrovascular disease (23,942) - or with none of these (24,624; comparison group).

British drug discovery company C4X Discovery said AstraZeneca had signed a licence worth up $402 million to develop an oral therapy for the treatment of inflammatory and respiratory diseases using its NRF2 Activator programme. The Manchester-based company said on Monday (November 28) it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront. In addition, C4XD said it would receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialisation of any treatment.

The Pharmaceutical Services Negotiating Committee (PSNC) has commissioned Nuffield Trust and The King's Fund to develop a new vision and strategic options for community pharmacy. The report is expected to be published in early summer next year, to underpin the future strategy for the sector. It will also support negotiations between PSNC and policymakers as the current five-year Community Pharmacy Contractual Framework (CPCF) comes to an end. Those negotiations will decide what happens after April 2024, and they will be critical to the future of the sector. The development of a compelling vision and an effective strategy for community pharmacy was a key recommendation from the Pharmacy Representation Review Steering Group (RSG). It forms one of the workstreams of the Transforming Pharmacy Representation Programme (TAPR) currently being undertaken by PSNC. But it is also a project that PSNC wants to undertake anyway to help lay the foundations for those crucial upcoming negotiations.

Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.

In response to the concerning surge in youth vaping, the UK government in January announced its decision to ban disposable vapes as a measure to safeguard the health of children. Prime Minister Rishi Sunak stated that while the long-term impacts of vaping were uncertain, the nicotine present in these products can be highly addictive. Therefore, he emphasised that "marketing vapes to children is not acceptable." Now, there's a stronger reason to crack down on vape sales as a new study has revealed that vaping or the use of e-cigarettes may increase the risk of developing heart failure. The study, which involved 175,000 adults in the United States, found that those who use e-cigarettes were 19 per cent more likely to develop heart failure over a four-year period. Dr Yakubu Bene-Alhasan, lead author of the study, from MedStar Health in Baltimore, underscored that an increasing number of studies are linking e-cigarettes with harmful effects, suggesting vaping "might not be as safe as previously thought." With further research, Dr Bene-Alhasan's team plans to uncover "a lot more about the potential health consequences and improve the information out to the public."

A final review of gender services provided by the NHS has uncovered significant shortcomings, leaving thousands of vulnerable children questioning their gender identity without adequate support. The report, led by Dr. Hilary Cass, a prominent consultant paediatrician, highlights the use of unproven treatments and the detrimental impact of the polarized trans debate on gender care provision. The investigation, commissioned by NHS England in 2020, focused on the Tavistock and Portman NHS mental health trust's gender identity development services (Gids), which treated around 9,000 children and young people between 2009 and 2020. Shockingly, the review found that despite limited evidence of effectiveness and potential health risks, puberty blockers and cross-sex hormones were routinely administered. Dr. Cass emphasized that the "rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health. The effect on cognitive and psychosexual development remains unknown."

In a new study, men who took phosphodiesterase type 5 inhibitors (PDE5Is), such as Viagra (sildenafil; Pfizer), for treatment of erectile dysfunction, were found to be 18 per cent less likely to develop Alzheimer's compared to those who did not take the drugs. The results of the population-based cohort study were published in Neurology on 7 February 2024. Researchers at University of Oxford examined IQVIA Medical Research Data UK records of 269,725 men, who were diagnosed with erectile dysfunction between January 2000 and March 2017. None of the participants had any memory or thinking problems at the start of the study and they were followed for an average of 5.1 years. During the study, 749 out of 1,119 participants taking erectile dysfunction drugs developed Alzheimer's disease.

Change can be intrinsically frightening, but one key to successful personal development is mastering that fear.

Take Home: UMass Medical School and WPI have developed an app that can detect atrial fibrillation.  This moves connected and mobile health closer to reality.  The really important development with this approach might allow us to treat patients who have AF intermittently (paroxysmal) differently than we currently do.  Because we are worried about stroke, patients now get blood thinners all the time because we are concerned that they will have recurrences without knowing about it.  With this technology, in the future, we might see validation of a strategy that allows use of blood thinners when patients are in AF only, sometimes called a pill in the pocket.

There is big gap between the healthcare facilities provided by the developing nations and developed nations. Vaccination programs help developing countries, defend deadliest of diseases. Hilleman Labs, a partner of Merck & Co. and Wellcome Trust

Softtech World is a leading Website development & Designing Company in India. We also specialize in Web designing, eCommerce & business applications. Get your dream website at cheapest price. For any query, Please write to us at:  info@softtechworld.com Or Call to us at: +91 9999819534 Or Visit at: http://www.softtechworld.com

C.P.Wheelchair Folding with Head & Side Supports, Chest-Straps and Push Breaks is most suitable for children with special needs. Wheelchair has adjustable Seat Tilt and Backrest Tilt with adjustable Armrest & Elevating Footrest for comfortable positioning of the child. The wheelchair provides a comfortable and efficient mode of ambulation for child with cerebral palsy wheel chair. Child with c.p. wheelchair must learn to manage the wheelchair skillfully, safely, and capably, learn to measure space and judge speed and distance with the wheelchair. The c.p. wheelchair is a relief to recreation and socialization. Features: Frame : Tubular Aluminum Light Weight Frame with powder coated finish. Seat : 33cm wide. Seat-Tilt is adjustable with Hand lever for comfort of child. Backrest : Adjustable recline for comfortable back-support. Useful for the children, who have tendency to bend forward. Armrest : Adjustable in Height & are Detachable for easy transfer & fitted with Skirt Guard & Arm-Supports. Leg-rest: Detachable, Elevating and Swing-away Leg-rests are fitted with Leg supports. Front Wheel : 15cm dia. Casters with solid tyres. Rear Wheel : 40cm dia. Mag wheels with solid Tyres. Break : Forward Push safety / parking Breaks. Safety : Back is fitted with Side-supports & Chest-Straps to support & Hold the child. Seat is fitted with an abductor block to support the child. Cerebral Palsy Wheelchair The wheelchair provides a comfortable and efficient mode of ambulation for child with cerebral palsy or persons whose physical dysfunction. The cerebral palsy wheelchair is essential to making activities. Child with cerebral palsy must learn to manage the wheelchair skillfully, safely, and efficiently, learn to measure space and judge speed and distance with the wheelchair. Cerebral palsy (CP) is a group of conditions caused by medical abnormalities in the development of a fetus or the early life of a child. These lead to damage or del

Pediatric Wheelchair are fabricated using finest grade raw materials such as aluminum, ms steel pipe, stainless steel pipe.Pediatric Wheelchairs specially designed wheelchairs are suitable for children up to 15 years of age and are capable for 50 kgs. Our range of pediatric wheelchairs are easy to handle and can be used for indoor as well as outdoor purposes.Cerebral palsy is a very common childhood condition, with a consistent prevalence rate estimated at 2/ 1000 children in developed countries. Cerebral palsy occurs when parts of the brain that control muscles are damaged, causing varying degrees of lifelong disability. There is a wide spectrum disability within CP, ranging from mild physical disabilities to more severe cognitive and physical disabilities both. Types of Cerebral Palsy: Spastic CP Ataxic CP Mixed CP Monoplegic CP Spastic Cerebral Palsy: This is the most common type of CP. Spastic is a condition of muscular rigidity or spasm that children with CP have. Muscle stiffness causes the body to adopt abnormal positions that the child cannot easily move out from. Movements are awkward and limited or restricted. Ataxic Cerebral Palsy: Ataxic means unsteady or shaky movements that are less pronounced than in athetosis. These unsteady movements are observed when a child tries to carry out an activity. For example, when he/she reaches for an object or a toy, he/she may miss the target in the first attempt. Due to poor balance, standing and walking may take longer to learn. Mixed Cerebral Palsy: Children with mixed CP show features of more than one type of cerebral palsy. For example, some children have spastic CP with athetosis. Monoplegic: Occasionally a child has monoplegic CP, in which only one limb is affected. Monoplegic cases are few. CP Child Chair CP is usually caused by factors prior to birth: lack of oxygen passed to the child before birth, via infection spreading from mother to baby or by genetic disorder.

We have the best resources for kol development, medical content writer, medical content development services, medical information system, technical it support, medical e-sales training module, medical product launch